# OnCo record dostarlimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dostarlimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dostarlimab" ;
  schema:name "Dostarlimab"@en ;
  schema:description "Dostarlimab is a PD-1 blocker famous for making rectal cancer disappear without surgery in every patient with a mismatch-repair-deficient tumour."@en ;
  schema:url <https://onco.cc/drugs/dostarlimab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dostarlimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q85757472> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dostarlimab>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22JEMPERLI%22>, <https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Jemperli" ;
  onco:approval "US 2021: dMMR recurrent/advanced endometrial cancer; dMMR solid tumours", "US 2024: Primary advanced/recurrent endometrial cancer with chemotherapy (all-comers)" ;
  onco:acceleratedApproval "US 2021-04-22: Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.", "US 2021-08-17: Treatment for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options" ;
  onco:acceleratedApprovalConfirmed "US 2023-02-09: Adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen." ;
  onco:related <https://onco.cc/biomarkers/dmmr-ihc/> ;
  onco:cancers <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/msi-high-colorectal/>, <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/uterine-carcinosarcoma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:trials <https://onco.cc/trials/nct06521567/>, <https://onco.cc/trials/nct05565378/>, <https://onco.cc/trials/nct06640049/>, <https://onco.cc/trials/nct06062420/>, <https://onco.cc/trials/nct06256588/>, <https://onco.cc/trials/nct07108270/>, <https://onco.cc/trials/nct06567782/>, <https://onco.cc/trials/nct06317311/>, <https://onco.cc/trials/nct03602859/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/trials/nct06472076/>, <https://onco.cc/trials/nct06796907/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/> .